With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.